Compass Pathways (NASDAQ:CMPS) Shares Gap Up – Here’s Why

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $10.37, but opened at $11.64. Compass Pathways shares last traded at $10.8880, with a volume of 1,815,394 shares traded.

Key Stories Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $70 price target on Compass Pathways while raising several earnings estimates for 2026–2027, signaling improving long-term expectations for the company. HC Wainwright estimate updates
• Positive Sentiment: Retail-focused headlines suggest traders are betting on a major FDA-related catalyst, which has helped fuel renewed momentum in the shares. CMPS stock breaking out again
• Positive Sentiment: Unusually heavy options activity on Monday showed strong speculative interest, with call buying running well above normal levels and reinforcing bullish sentiment. Options trading activity
• Neutral Sentiment: Additional coverage highlighted Compass Pathways as a “hot” psychedelics stock, reflecting strong trader enthusiasm but not adding new fundamental information. Psychedelics stock coverage
• Negative Sentiment: One research update from LifeSci Capital reportedly cut earnings estimates for Compass Pathways, which could temper enthusiasm if investors focus on execution risk and continued losses. LifeSci Capital cuts estimates

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CMPS shares. Canaccord Genuity Group cut their target price on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, March 26th. Compass Point set a $15.00 target price on shares of Compass Pathways in a research report on Thursday, February 12th. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. UBS Group set a $18.00 price target on shares of Compass Pathways in a research note on Thursday, May 7th. Finally, Maxim Group boosted their price target on shares of Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.58.

Compass Pathways Trading Down 4.6%

The stock has a market capitalization of $1.36 billion, a P/E ratio of -3.20 and a beta of 2.39. The firm’s 50 day moving average price is $7.37 and its 200 day moving average price is $6.80. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. As a group, equities research analysts expect that Compass Pathways PLC Sponsored ADR will post -0.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Pathways

A number of hedge funds and other institutional investors have recently bought and sold shares of CMPS. Royal Bank of Canada grew its holdings in Compass Pathways by 49.8% in the first quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock worth $256,000 after purchasing an additional 29,733 shares during the period. Acadian Asset Management LLC grew its holdings in Compass Pathways by 42.0% in the first quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock worth $686,000 after purchasing an additional 71,112 shares during the period. Nantahala Capital Management LLC grew its holdings in Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after purchasing an additional 1,350,698 shares during the period. Balyasny Asset Management L.P. grew its holdings in Compass Pathways by 38.0% in the second quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company’s stock worth $2,394,000 after purchasing an additional 235,345 shares during the period. Finally, Northeast Financial Consultants Inc purchased a new stake in Compass Pathways in the second quarter worth about $59,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.